FRNM

Freenome Inc

11.24

Nov 11 • 1:20 PM ET +0.47 (4.36%)

Healthcare Diagnostics & Research USA Small NASD

Nov 10, 7:15 PMFreenome Inc reports Q3 2026 results with non-GAAP EPS $0.58, revenue $183.5M, beats estimates, issues 2026 revenue guidance $192–$194M

Peers: GH GRAL BLLN NTRA CSTL VCYT ADPT BNR LUCD AIDX

| Held by: ARKG VXF SCHA ITOT ONEQ SCHB TMED TNXT TSEE

Scroll to Statements

Index	-
Market Cap	1.21B
Enterprise Value	979.39M
Income	59.20M
Sales	183.49M
Book/sh	4.34
Cash/sh	4.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	3
IPO	Jun 12, 2024

P/E	22.60
Forward P/E	-
PEG	-
P/S	6.58
P/B	2.59
P/C	2.81
P/FCF	-
EV/EBITDA	13.51
EV/Sales	5.34
Quick Ratio	12.68
Current Ratio	12.73
Debt/Eq	0.42
LT Debt/Eq	0.39
Option/Short	No / Yes

EPS (ttm)	0.50
EPS next Y	-
EPS next Q	-0.61
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-123.69%
Sales Y/Y TTM	-
EPS Q/Q	4327.48%
Sales Q/Q	-
Earnings	Nov 10 AMC
EPS/Sales Surpr.	321.82% 116.02%

Insider Own	29.11%
Insider Trans	0.00%
Inst Own	35.09%
Inst Trans	14.87%
ROA	14.34%
ROE	20.80%
ROIC	8.82%
Gross Margin	96.48%
Oper. Margin	36.24%
Profit Margin	32.27%
SMA20	-7.37%
SMA50	-20.84%
SMA200	-9.38%
Trades

Shs Outstand	110.87M
Shs Float	76.17M
Short Float	6.08%
Short Ratio	5.34
Short Interest	4.63M
52W High	17.50 -35.77%
52W Low	9.71 15.76%
Volatility	10.87% 8.49%
ATR (14)	1.01
RSI (14)	39.42
Beta	0.68
Rel Volume	1.04
Avg Volume	868.39K
Volume	553,668

Perf Week	-0.53%
Perf Month	-11.08%
Perf Quarter	-3.19%
Perf Half Y	-0.53%
Perf YTD	-13.74%
Perf Year	5.05%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	18.00
Prev Close	10.77
Price	11.24
Change %	4.36%

Consensus

Strong Buy

Avg. Price Target

$18.00

Implied Upside

+60.1%

Analysts5incl. previous ratings

Rating Distribution5 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 20, 2026	Initiated	GGuggenheim	Buy	$21	+86.8%
Aug 18, 2026	Initiated	TTD Cowen	Buy	$17	+51.2%
Aug 17, 2026	Initiated	JJefferies	Buy	$17	+51.2%
Aug 17, 2026	Initiated	BBTIG Research	Buy	$17	+51.2%
Aug 14, 2026	Initiated	LLeerink Partners	Outperform	$18	+60.1%

Nov-10-26 04:01PM	Freenome Reports Third Quarter 2026 Financial Results (GlobeNewswire)
Oct-20-26 08:30AM	Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen Lung Test With FDA-Approved SimpleScreen CRC Option (GlobeNewswire) +11.85%
Oct-15-26 04:29PM	Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026 (GlobeNewswire)
Oct-11-26 01:00PM	Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 (GlobeNewswire)
Aug-12-26 09:00AM	FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen Lung Cancer Screening Test (GlobeNewswire)
08:00AM	Loading…
Jul-27-26 08:00AM	FDA Approves Freenome's SimpleScreen CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S. (GlobeNewswire)

Freenome, Inc. operates as an early detection company, which engages in the development of blood-based screening tests to detect cancer. Its proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The company was founded by Riley Ennis in 2014 and is headquartered in Brisbane, CA.

CEO & DirectorMr. Aaron Elliott Ph.D.

Co-Founder & Chief Product OfficerMr. Riley Ennis

Chief Financial OfficerMr. Linh H. Le

MHSMr. Cheng-Ho Lin M.D.

Chief Legal OfficerMr. Thomas F. Fitzpatrick J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

FRNM

Freenome Inc

Upgrade your Finviz experience

All the Features.
Half the Price.